Viking Therapeutics (VKTX) Non-Current Deffered Revenue (2015 - 2018)

Viking Therapeutics (VKTX) has 4 years of Non-Current Deffered Revenue data on file, last reported at $12000.0 in Q4 2018.

• For the quarter ending Q4 2018, Non-Current Deffered Revenue changed N/A year-over-year to $12000.0; the trailing twelve-month figure through Dec 2018 stood at $12000.0 (changed N/A YoY), and the FY2018 full-year result was $12000.0, changed N/A from the prior year.
• Non-Current Deffered Revenue improved to $12000.0 in Q4 2018, from $6054.0 in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $31239.0 in Q4 2015 to a low of $6054.0 in Q2 2017.
• A 4-year average of $18706.3 and a median of $19149.0 in 2015 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue advanced 6.93% in 2016 and slumped 75.44% in 2017, its largest moves.
• Tracing VKTX's Non-Current Deffered Revenue over 4 years: stood at $31239.0 in 2015, then plunged by 47.8% to $16307.0 in 2016, then slumped by 62.87% to $6054.0 in 2017, then surged by 98.22% to $12000.0 in 2018.
• Business Quant data shows VKTX's Non-Current Deffered Revenue at $12000.0 in Q4 2018, $6054.0 in Q2 2017, and $10862.0 in Q1 2017.